This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Malignant neoplasm of other and unspecified male genital organs, including Hilmo
C3_MALE_GENITAL_NAS_WIDE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleonly males |
244368 |
2. Check conditionsNone |
244368 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
72 |
4. Check minimum number of eventsNone |
72 |
5. Include endpointsNone |
72 |
6. Filter based on genotype QC (FinnGen only) |
66 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of other and unspecified male genital organs, including Hilmo
based on the number of shared cases.
Similar with more cases:
- malignant neoplasm of male genital organs, including Hilmo
- Solid cancers, including Hilmo
- Malignant neoplasm, wide definition
- Malignant neoplasm, including Hilmo
- Neoplasms
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 66 | - | 66 |
| Unadjusted period prevalence (%) | 0.03 | - | 0.03 |
| Median age at first event (years) | 66.19 | - | 66.19 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 68
- Matched controls
- 680
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
20.9
19
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
19.7
18
*
KFC00
NOMESCO Finland
Unilateral orchiectomy
129.2
18.6
19
*
130
Kela drug reimbursment
Malignant tumour
+∞
17.4
16
*
116
Kela drug reimbursment
Prostate cancer
+∞
12.9
12
*
C63.2
ICD-10 Finland
Malignant neoplasm: Scrotum
+∞
10.7
10
*
H02AB02
ATC
dexamethasone; systemic
64.5
10.0
11
*
C63.9
ICD-10 Finland
Malignant neoplasm: Male genital organ, unspecified
+∞
9.6
9
*
C63.0
ICD-10 Finland
Malignant neoplasm: Epididymis
+∞
9.6
9
*
L02AE02
ATC
leuprorelin; implant, parenteral
+∞
9.6
9
*
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
17.2
9.2
14
10
N02AA05
ATC
oxycodone; systemic
5.6
9.0
21
50
D40.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Testis
102.2
8.6
9
*
L02BB03
ATC
bicalutamide; oral
+∞
8.5
8
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
+∞
8.5
8
*
NE1CG
NOMESCO Finland
Pelvic, hip and femur extensive MRI examination with high intensity magnet
+∞
8.5
8
*
WX408
NOMESCO Finland
General anesthesy, balanced
4.7
8.3
26
79
QX3HE
NOMESCO Finland
Ultrsound examination of lesion close to skin
76.8
6.5
7
*
A04AA01
ATC
ondansetron; systemic, rectal
20.4
6.5
9
5
Z51.5
ICD-10 Finland
Palliative care
10.1
6.4
12
14
WF002
NOMESCO Finland
Radical radiotherapy
+∞
6.3
6
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
6.3
6
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
6.3
6
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
6.3
6
*
JN4BD
NOMESCO Finland
Extensive body CT
11.7
6.3
11
11
UKC02
NOMESCO Finland
Cystoscopy
3.8
6.0
24
85
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
24
51
6.73
11.79
4.5
1.8
263.25
238.04
u/l
0.25
24
46
27
110
3.41
5.41
3.9
2.5
—
—
—
0
0
22
84
3.39
4.82
4.8
2.6
1.52
1.07
e6/l
0.17
14
44
36
190
2.90
4.46
4.8
3.0
—
—
estimate
—
0
0
12
32
4.33
3.61
24.1
25.5
15.26
15.53
%
0.12
12
32
39
234
2.56
3.52
17.6
9.5
1.18
1.20
mmol/l
0.47
39
213
23
107
2.74
3.47
2.7
1.6
28.74
29.21
s
0.23
23
102
9
21
4.77
3.12
1.3
5.1
—
—
—
0
0
27
146
2.41
2.94
5.9
2.7
0.89
0.33
e6/l
0.30
20
104
15
61
2.87
2.86
21.3
20.6
115.27
121.44
g/l
0.58
15
61
18
83
2.59
2.71
4.7
2.8
1.43
0.64
e6/l
—
10
42
21
105
2.45
2.68
2.7
1.6
—
—
—
0
0
39
255
2.24
2.66
12.6
3.9
12.63
14.30
umol/l
0.44
39
243
18
84
2.55
2.64
3.2
3.0
2.15
2.13
g/l
0.07
18
76
10
32
3.48
2.56
1.9
1.4
—
—
—
0
0
6
12
5.36
2.46
2.7
2.6
3.73
4.17
g/l
—
6
12
11
40
3.08
2.41
1.6
1.5
—
—
—
0
0
17
81
2.47
2.37
3.4
3.1
21.54
23.62
%
0.46
17
75
11
41
3.00
2.34
1.5
1.4
58.70
66.00
g/l
1.34
11
33
30
185
2.11
2.29
6.2
2.9
—
—
—
0
0
41
286
2.09
2.24
16.5
5.4
4.52
4.54
e9/l
0.02
35
244
5
10
5.30
2.11
1.2
1.1
—
—
—
0
0
18
94
2.24
2.04
3.6
2.9
11.39
13.00
umol/l
0.73
18
85
5
11
4.81
1.97
1.4
1.4
—
—
—
0
0
17
88
2.24
1.96
19.2
9.8
103.06
104.18
mmol/l
0.38
17
88
49
377
2.07
1.92
13.9
5.6
82.53
79.37
u/l
0.19
49
350
15
76
2.25
1.81
2.9
1.7
—
—
—
0
0
5
14
3.76
1.64
2.4
1.6
84.40
80.36
%
—
5
14
5
14
3.76
1.64
2.4
1.7
253.80
225.64
%
—
5
14
5
14
3.76
1.64
1.6
1.3
—
—
—
0
0
43
329
1.84
1.57
12.2
7.0
6.89
6.81
mmol/l
0.08
43
317
15
82
2.06
1.50
2.7
1.5
—
—
—
0
0
29
200
1.78
1.47
4.3
2.9
250.73
166.66
ug/l
0.39
29
182
5
16
3.29
1.46
2.0
1.1
—
—
—
0
0
36
266
1.75
1.43
5.2
3.1
265.00
0.00
estimate
—
6
53
22
143
1.80
1.34
3.1
1.9
2.90
2.64
mg/l
0.40
22
118
48
391
1.77
1.30
45.6
19.2
14.22
13.73
%
1.41
48
386
5
20
2.61
1.17
1.2
1.2
30.18
36.84
mg/l
—
5
20
5
20
2.61
1.17
1.2
1.2
30.16
47.91
mg/l
—
5
20
19
123
1.76
1.16
6.5
4.0
43.11
399.23
ng/l
1.02
19
105
54
464
1.80
1.11
31.0
15.4
65.61
74.53
ml/min/173m2
2.19
48
429
7
34
2.18
1.06
1.3
1.4
—
—
—
0
0
7
37
1.99
0.97
5.3
5.4
89.70
116.56
ng/l
—
7
28
11
64
1.86
0.92
3.7
3.5
17.14
8.57
ug/l
0.31
11
55
12
74
1.75
0.85
4.2
3.5
5.87
5.89
kpa
0.03
12
69
12
75
1.73
0.81
4.1
3.4
-0.77
1.60
mmol/l
0.59
12
60
5
23
2.26
0.78
2.6
1.4
—
—
—
0
0
37
305
1.47
0.78
7.3
3.8
26.82
25.75
%
0.11
19
146
5
24
2.17
0.76
2.6
1.5
—
—
—
0
0
31
251
1.43
0.70
2.8
2.4
—
—
—
0
0
6
34
1.84
0.60
1.7
1.3
—
—
—
0
0
55
511
1.40
0.44
46.3
21.6
139.75
139.64
mmol/l
0.06
55
503
55
511
1.40
0.44
47.0
21.6
4.02
4.05
mmol/l
0.39
55
502
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.4
—
0.15
—
0
6
0
18
0.00
0.40
0.0
1.0
—
—
—
0
0
5
35
1.46
0.40
1.0
2.5
0.94
1.20
%
—
5
35
25
211
1.29
0.39
3.2
2.7
1.18
0.84
ug/l
0.22
20
141
56
528
1.34
0.34
53.0
23.6
91.38
91.62
fl
0.15
56
522
56
529
1.33
0.32
53.4
23.8
127.57
139.05
g/l
3.87
56
524
56
529
1.33
0.32
57.9
24.6
38.47
41.27
%
3.20
56
523
7
56
1.28
0.30
6.6
3.1
—
—
—
0
0
23
260
0.83
0.25
4.5
4.2
37.78
62.14
ng/l
0.77
18
207
29
260
1.20
0.25
2.5
2.1
86.66
91.30
pmol/l
0.22
17
149
54
513
1.26
0.25
18.6
10.2
29.17
26.22
u/l
0.56
54
487
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
33
304
1.17
0.20
3.1
3.4
104.36
56.67
u/l
0.35
33
278
9
108
0.81
0.14
2.7
2.0
1151.24
1269.85
nmol/l
—
9
85
47
489
0.87
0.14
6.3
6.4
2.31
2.44
mmol/l
0.62
47
451
49
474
1.12
0.10
6.2
7.6
40.22
40.90
mmol/mol
0.26
49
438
6
70
0.84
0.08
17.7
8.2
—
—
—
0
0
47
479
0.94
0.03
5.4
5.4
6.03
6.16
mmol/l
0.51
47
428
0
7
0.00
-0.00
0.0
1.6
—
537.29
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
39.35
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_MALE_GENITAL_NAS_WIDE – Malignant neoplasm of other and unspecified male genital organs, including Hilmo
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).